MapLight Therapeutics, Inc. (MPLT)
| Market Cap | 765.28M |
| Revenue (ttm) | n/a |
| Net Income | -229.83M |
| EPS | -7.42 |
| Shares Out | 55.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 550,841 |
| Open | 13.03 |
| Previous Close | 13.14 |
| Day's Range | 13.00 - 14.14 |
| 52-Week Range | 9.10 - 40.43 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.54 (+92.74%) |
| Earnings Date | Aug 13, 2026 |
About MPLT
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric co... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MPLT stock is "Strong Buy." The 12-month stock price target is $26.54, which is an increase of 92.74% from the latest price.
News
MapLight Therapeutics price target lowered to $43 from $45 at Needham
Needham lowered the firm’s price target on MapLight Therapeutics (MPLT) to $43 from $45 and keeps a Buy rating on the shares. The firm is updating its model to reflect…
MapLight Therapeutics announces $150M private placement
MapLight Therapeutics (MPLT) announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing for gros...
MapLight Therapeutics reports Q2 EPS ($1.32), consensus ($1.31)
“With positive Phase 2 data from ZEPHYR and continued progress in VISTA, we are focusing our efforts on advancing ML-007C-MA in both schizophrenia and ADP,” said Chris Kroeger, Co-Founder and…
MapLight Therapeutics price target lowered to $31 from $35 at Raymond James
Raymond James lowered the firm’s price target on MapLight Therapeutics (MPLT) to $31 from $35 and keeps a Strong Buy rating on the shares. Following the ZEPHYR readout, the firm’s…
MapLight Therapeutics price target lowered to $21 from $24 at Canaccord
Canaccord analyst Sumant Kulkarni lowered the firm’s price target on MapLight Therapeutics (MPLT) to $21 from $24 and keeps a Buy rating on the shares. The firm said their Q2…
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C...
MapLight Therapeutics Announces $150 Million Private Placement Financing
SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering ...
MapLight Therapeutics Quarterly report: Q2 2026
MapLight Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
MapLight Therapeutics Earnings release: Q2 2026
MapLight Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
MapLight Therapeutics downgraded to Neutral from Buy at UBS
UBS downgraded MapLight Therapeutics (MPLT) to Neutral from Buy with a price target of $13, down from $52. Recent Phase 2 schizophrenia results for ML-007 show low levels of efficacy…
MapLight Therapeutics downgraded to Neutral from Buy at UBS
UBS downgraded MapLight Therapeutics (MPLT) to Neutral from Buy with a $13 price target
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofMapLig...
MapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum
Craig-Hallum analyst Adam Vogel lowered the firm’s price target on MapLight Therapeutics (MPLT) to $25 from $40 and keeps a Buy rating on the shares. The firm notes ML-007 positive…
MapLight Therapeutics price target lowered to $24 from $43 at Canaccord
Canaccord lowered the firm’s price target on MapLight Therapeutics (MPLT) to $24 from $43 and keeps a Buy rating on the shares. The firm updated its model following the company’s…
MapLight downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded MapLight Therapeutics (MPLT) to Equal Weight from Overweight with a price target of $21, down from $34. While the ZEPHYR study shows ML-007 is pharmacologically active in…
MapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on MapLight Therapeutics (MPLT) to $26 from $45 and keeps a Buy rating on the shares after the company reported…
MapLight's schizophrenia drug fails once-daily test, shares plunge
MapLight Therapeutics said on Monday its schizophrenia drug failed to show statistically significant symptom improvement in the once-daily dosing arm of a mid-stage trial, sending its shares tumbling...
MapLight Therapeutics Transcript: Study result
The phase II ZEPHYR study of ML-007C-MA in schizophrenia met its primary endpoint, showing significant efficacy on PANSS and cognitive measures, with a favorable safety and tolerability profile. The cognitive benefit appears independent of antipsychotic effects, supporting further pivotal studies and expansion into Alzheimer's disease psychosis.
MapLight Therapeutics Slides: Study result
MapLight Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
MapLight Therapeutics Press release: Study result
MapLight Therapeutics issued a press release on July 27, 2026, disclosing material business information to investors.
MapLight Therapeutics announces topline results from ZEPHYR trial
MapLight Therapeutics (MPLT) announced topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic, i...
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place...
MapLight Therapeutics price target raised to $43 from $35 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on MapLight Therapeutics (MPLT) to $43 from $35 and keeps a Buy rating on the shares. The firm said the company…
MapLight Therapeutics price target raised to $52 from $48 at UBS
UBS raised the firm’s price target on MapLight Therapeutics (MPLT) to $52 from $48 and keeps a Buy rating on the shares. The upcoming Phase 2 readout for ML-007 in…
BMO starts MapLight at Outperform, eyes validation data in August
BMO Capital initiated coverage of MapLight Therapeutics (MPLT) with an Outperform rating and $46 price target MapLight’s dual muscarinic agonist ML-007C-MA looks to demonstrate improved tolerability w...